vTv Therapeutics (NASDAQ:VTVT) Posts Quarterly Earnings Results, Beats Estimates By $0.15 EPS

vTv Therapeutics (NASDAQ:VTVT) posted its quarterly earnings data on Thursday. The biotechnology company reported ($0.94) earnings per share for the quarter, topping the consensus estimate of ($1.09) by $0.15, FiscalAI reports.

vTv Therapeutics Trading Down 9.5%

VTVT stock traded down $2.29 during trading on Thursday, reaching $21.74. 17,774 shares of the stock were exchanged, compared to its average volume of 51,027. The firm’s 50 day moving average is $29.70 and its 200 day moving average is $33.36. vTv Therapeutics has a twelve month low of $21.72 and a twelve month high of $44.00. The firm has a market cap of $85.63 million, a P/E ratio of -20.51 and a beta of 0.28.

Wall Street Analyst Weigh In

Several research firms recently commented on VTVT. Zacks Research raised vTv Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Monday, September 7th. HC Wainwright dropped their price target on vTv Therapeutics from $45.00 to $42.00 and set a “buy” rating on the stock in a research note on Thursday, August 6th. Weiss Ratings cut vTv Therapeutics from a “sell (d+)” rating to a “sell (d-)” rating in a report on Tuesday, August 11th. Lifesci Capital raised shares of vTv Therapeutics to a “strong-buy” rating in a research report on Wednesday, September 2nd. Finally, Wall Street Zen lowered shares of vTv Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, October 24th. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $55.83.

About vTv Therapeutics

vTv Therapeutics Inc (NASDAQ: VTVT) is a clinical-stage biopharmaceutical company focused on developing orally administered therapies for metabolic and neurological diseases. The company uses small-molecule drug discovery and development programs to address conditions with significant unmet medical needs.

Its lead product candidate is TTP399, an oral, liver-selective glucokinase activator being developed as an adjunctive treatment for people with type 1 diabetes. The company has also developed other investigational therapies, including compounds targeting type 2 diabetes, obesity and Alzheimer’s disease.